Published in

American Association for Cancer Research, Clinical Cancer Research, 16(29), p. 2961-2963, 2023

DOI: 10.1158/1078-0432.ccr-23-1107

Links

Tools

Export citation

Search in Google Scholar

Keeping It in the Family: HER3 as a Target in Brain Metastases

Journal article published in 2023 by Sheheryar Kabraji ORCID, Nancy U. Lin ORCID
This paper was not found in any repository, but could be made available legally by the author.
This paper was not found in any repository, but could be made available legally by the author.

Full text: Unavailable

Green circle
Preprint: archiving allowed
Upload
Orange circle
Postprint: archiving restricted
Upload
Red circle
Published version: archiving forbidden
Policy details
Data provided by SHERPA/RoMEO

Abstract

SummaryIn 180 patients with metastatic breast cancer and non–small cell lung cancer (NSCLC), HER3 expression was found in >70% of brain metastases (BM). HER3-targeting antibody–drug conjugates have demonstrated efficacy in HER3-expressing metastatic breast cancer and NSCLC. Thus, HER3 expression by IHC may be a biomarker for development of HER3-targeting BM-specific therapeutics.See related article by Tomasich et al., p. 3225